Want to see TFX full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.27Last Year’s EPS
3.73Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.Company Guidance
Revenue Growth — Q1 2026
Total continuing operations revenue of $548.3 million in Q1 2026, up 32.3% year-over-year on a GAAP basis and up 5.1% on a pro forma adjusted constant currency basis.
Segment Performance
Surgical revenue grew 9.9% to $106.8 million (driven by ligation clips and instrument order timing); Vascular grew 4.8% to $236.8 million (hemostatic and central venous products); Interventional was $204.7 million, up 3% (intraosseous, right heart and complex catheters).
Strategic M&A and Portfolio Optimization
Completed acquisition of BIOTRONIK's Vascular Intervention business (July 2025) and announced divestitures of acute care, interventional urology and OEM businesses (announced Dec 2025) to create a focused Vascular Access, Interventional and Surgical company; expected net proceeds of ~ $1.8 billion after tax.
Capital Allocation Plan
Announced intention to use divestiture proceeds to fund up to $1 billion share repurchase program and repay $800 million of debt; opportunistic open-market repurchases expected to begin in Q2 2026.
Clinical and R&D Progress — Freesolve
Freesolve (drug-eluting resorbable magnesium scaffold) BIOMAG-II European pivotal trial is enrolling ahead of expectations with a late-2027 data readout targeted; BIOMAG-III (U.S.) planned to initiate in 2026.
Cost Savings and Restructuring
Launched a multiyear restructuring plan expected to deliver approximately $50 million of annual pretax cost savings upon completion (savings to accelerate in H2 2026 and complete by mid-2028).
Guidance and Forward Profile
Maintained 2026 pro forma adjusted constant currency revenue growth guidance of 4.5%–5.5% and adjusted EPS guidance of $6.25–$6.55; company expects a steady-state adjusted operating margin of ~23% post-separation (about 400 bps above fully burdened 2026 guidance).
Governance and Leadership
Board refresh (nomination of Michael J. Tokich; Andrew Krakauer to succeed as Chair) and appointment of new CEO Jason Weidman effective June 8, 2026, aimed at accelerating growth and execution.
TFX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TFX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $122.91 | $131.34 | +6.86% |
Feb 26, 2026 | $111.28 | $118.37 | +6.37% |
Nov 06, 2025 | $123.68 | $107.58 | -13.02% |
Jul 31, 2025 | $112.62 | $118.15 | +4.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Teleflex (TFX) report earnings?
Teleflex (TFX) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Teleflex (TFX) earnings time?
Teleflex (TFX) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TFX EPS forecast?
TFX EPS forecast for the fiscal quarter 2026 (Q2) is 1.27.